Priovant Therapeutics, a Roivant spinout, reported that brepocitinib — a TYK2/JAK1 inhibitor obtained from Pfizer — significantly outperformed placebo in a small Phase 2 study of cutaneous sarcoidosis, producing marked lesion clearance. Investigators described effect sizes that exceeded expectations for this rare dermatologic condition and highlighted a favorable tolerability profile in the trial cohort. Company executives and external clinicians called the results encouraging for brepocitinib’s broader immunology development plan, including ongoing work in dermatomyositis. The data could accelerate Priovant’s regulatory and partnering discussions if replicated in larger trials; biopharma peers will assess how the TYK2/JAK1 profile stacks up across other inflammatory indications.